PakAryan
Iron
- Joined
- Mar 24, 2025
- Posts
- 92
- Reputation
- 74
Donald Trump has officially become the first president to implement pro-looksmaxxing policy by significantly reducing the price of leanmaxxing weight-loss GLP-1 drugs (realistically we are all buying from shady Chinese suppliers to save money anyway)
Source: https://www.nbcnews.com/news/amp/rcna242309
"President Donald Trump said Thursday his administration has reached a deal to lower the cost of the blockbuster GLP-1 weight loss drugs, Wegovy and Zepbound.
Under the deal, the monthly out-of-pocket cost of the drugs could range from $50 to around $350, depending on the dosage and insurance coverage.
On TrumpRx — the government’s discount platform for buying prescription drugs with cash — the average monthly cost for Wegovy and Zepbound will start at $350 and drop to $250 within the next two years, according to senior administration officials.
The drugmakers have voluntarily agreed to reduce the prices the government pays for all GLP-1 drugs already approved for diabetes and other indications to $245 a month across all non-starting doses. People on Medicare will pay no more than a $50 copay. People on Medicaid typically do not pay a copay.
The administration expects the direct-to-consumer pricing to be available by the end of the year on the TrumpRx site and Medicare coverage to be available by the middle of next year.
Meanwhile, the deal mentioned that starting doses of GLP-1 pills will cost $149. No GLP-1 pills for weight loss have been approved, although Novo Nordisk and Lilly are studying these formulations. Lilly said it has applied for a “priority voucher,” which would expedite the approval of a weight loss pill. A senior official said the administration expects that priority voucher will be approved Thursday."
Source: https://www.nbcnews.com/news/amp/rcna242309
"President Donald Trump said Thursday his administration has reached a deal to lower the cost of the blockbuster GLP-1 weight loss drugs, Wegovy and Zepbound.
Under the deal, the monthly out-of-pocket cost of the drugs could range from $50 to around $350, depending on the dosage and insurance coverage.
On TrumpRx — the government’s discount platform for buying prescription drugs with cash — the average monthly cost for Wegovy and Zepbound will start at $350 and drop to $250 within the next two years, according to senior administration officials.
The drugmakers have voluntarily agreed to reduce the prices the government pays for all GLP-1 drugs already approved for diabetes and other indications to $245 a month across all non-starting doses. People on Medicare will pay no more than a $50 copay. People on Medicaid typically do not pay a copay.
The administration expects the direct-to-consumer pricing to be available by the end of the year on the TrumpRx site and Medicare coverage to be available by the middle of next year.
Meanwhile, the deal mentioned that starting doses of GLP-1 pills will cost $149. No GLP-1 pills for weight loss have been approved, although Novo Nordisk and Lilly are studying these formulations. Lilly said it has applied for a “priority voucher,” which would expedite the approval of a weight loss pill. A senior official said the administration expects that priority voucher will be approved Thursday."
Last edited:
